title: Cost-effectiveness of antiepileptic drugs in migraine prophylaxis.
abstract: OBJECTIVE
  To analyze the cost-effectiveness of antiepileptics in migraine prophylaxis.
  
  
  METHODS
  A cost-effectiveness analysis was performed using efficacy data from three recent, double-blind, placebo-controlled, clinical trials of antiepileptic drugs studied for migraine prevention and cost data. Two measures of cost-effectiveness were used: cost per headache prevented and the cost-equivalent number.
  
  
  RESULTS
  In the double-blind, placebo-controlled, clinical trials evaluated, three antiepileptic drugs were shown to be effective in migraine prevention. All three antiepileptic drugs had high costs per migraine reduced. Gabapentin was the most costly at dollars 138.00 per migraine prevented, whereas the cost per migraine prevented with topiramate was US dollars 114.80 and with divalproex sodium was US dollars 48.00. For migraine prevention divalproex sodium became cost-effective with 10 migraines per month, whereas gabapentin and topiramate required considerably more migraines per month to be cost-effective.
  
  
  CONCLUSIONS
  Antiepileptic drugs have proven effectiveness in migraine prophylaxis. However, in patients responsive to their acute care medications, the antiepileptic drugs are only cost-effective for those patients with a high frequency of migraines and those with comorbid diseases. Future studies should be done with antiepileptic drugs in patients exhibiting a migraine frequency of 10 or more headaches per month.
authors.affiliation: Headache Wellness Center, Greensboro, North Carolina, 27401, USA. jadelman@triad.rr.com
authors.forename: James U
authors.initials: JU
authors.lastname: Adelman
authors.forename: Leon C
authors.initials: LC
authors.lastname: Adelman
authors.forename: Randal
authors.initials: R
authors.lastname: Von Seggern
mesh_terms: D000085:Acetates / Q000191:economics / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003509:Cyclohexanecarboxylic Acids; D005632:Fructose / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000077206:Gabapentin; D008881:Migraine Disorders / Q000188:drug therapy* / Q000191:economics; D008962:Models, Theoretical; D017366:Serotonin Receptor Agonists / Q000191:economics / Q000627:therapeutic use; D018170:Sumatriptan / Q000191:economics / Q000627:therapeutic use; D000077236:Topiramate; D014635:Valproic Acid / Q000191:economics / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D017366:Serotonin Receptor Agonists; D000077236:Topiramate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; D018170:Sumatriptan